Arecor Therapeutics plc

Equities

AREC

GB00BMWLM973

Biotechnology & Medical Research

Market Closed - London S.E. 16:35:20 22/07/2024 BST 5-day change 1st Jan Change
92.5 GBX 0.00% Intraday chart for Arecor Therapeutics plc -10.63% -49.32%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Arecor Therapeutics Raises GBP7 Million via Share Placing, Subscription, retail offer MT
Ingenta and Shearwater win deals AN
EARNINGS AND TRADING: Sound Energy sells part of Moroccan assets AN
Political turmoil hits euro and banks AN
Europe heads lower amid political turmoil in EU AN
AIM WINNERS & LOSERS: Arecor Therapeutics dives on funding needs AN
Arecor Therapeutics shares dive as says needs funding in third quarter AN
Europe sinks, euro down amid French snap election AN
Transcript : Arecor Therapeutics plc - Special Call
Arecor Therapeutics plc Announces Its Ultra-Concentrated, Ultra-Rapid Acting Insulins CI
Arecor Therapeutics' Investigational Insulin Shows Fast Absorption in Early-stage Study MT
Arecor Therapeutics hails positive profile for insulin AT278 AN
EARNINGS AND TRADING: Michelmersh continues with positive order intake AN
Transcript : Arecor Therapeutics plc, 2023 Earnings Call, May 16, 2024
Earnings Flash (AREC.L) ARECOR THERAPEUTICS Posts FY23 Revenue GBP4.6M MT
Earnings Flash (AREC.L) ARECOR THERAPEUTICS Reports FY23 Loss GBP-0.28 MT
Arecor Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Arecor Therapeutics collaborates with Medtronic on novel insulin AN
Arecor Therapeutics, Medtronic Team Up for Thermostable Insulin Development MT
Arecor and Medtronic Diabetes Collaboration CI
Arecor Therapeutics delays publication of 2023 results AN
Arecor Therapeutics plc Announces Delay in Publication of the Group's Final Results for the Year Ended 31 December 2023 CI
Arecor chief financial officer to leave in July after five years AN
Arecor Therapeutics CFO to Leave in July MT
Arecor Therapeutics plc Announces Stepping Down of Susan Lowther as Chief Financial Officer, Effective from July 22, 2024 CI
Chart Arecor Therapeutics plc
More charts
Arecor Therapeutics plc is a United Kingdom-based globally focused biopharmaceutical company. The Company, by applying its technology platform, Arestat, is developing an internal portfolio of products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver therapeutic products. Its portfolio includes AT247 - Ultra-Rapid Acting Insulin and AT278 - Ultra-Concentrated Ultra-Rapid Acting Insulin. Its lead product, AT247, is an Arestat enabled formulation of insulin designed to accelerate insulin absorption post injection, to enable effective management of blood glucose levels for people living with diabetes, particularly around difficult to manage mealtimes. The Company's AT278 is an ultra-concentrated novel formulation of ultra-rapid acting insulin. Its subsidiary, Tetris Pharma Ltd, has a portfolio of injectable products including Ogluo, which is a ready-to-use glucagon for emergency use to treat hypoglycemia.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.925 GBP
Average target price
5.007 GBP
Spread / Average Target
+441.26%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. AREC Stock
  4. News Arecor Therapeutics plc
  5. Earnings Flash (AREC.L) ARECOR THERAPEUTICS Posts FY23 Revenue GBP4.6M